One new overarching principle for @eular_org PsA recommendations: “The choice of treatment should take account of safety considerations regarding individual MoA to optimize the benefit-risk profile” Wonder what triggered that #EULAR2023 #oralsurveillance @RheumNow https://t.co/19BfJQz4Za